Last reviewed · How we verify

Aceclidine ophthalmic solution

LENZ Therapeutics, Inc · Phase 3 active Small molecule

Aceclidine ophthalmic solution is a Muscarinic receptor agonist Small molecule drug developed by LENZ Therapeutics, Inc. It is currently in Phase 3 development for Presbyopia (age-related loss of accommodation), Potentially glaucoma or ocular hypertension. Also known as: LNZ100, Aceclidine.

Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision.

Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision. Used for Presbyopia (age-related loss of accommodation), Potentially glaucoma or ocular hypertension.

At a glance

Generic nameAceclidine ophthalmic solution
Also known asLNZ100, Aceclidine
SponsorLENZ Therapeutics, Inc
Drug classMuscarinic receptor agonist
TargetMuscarinic acetylcholine receptors (M1, M3)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Aceclidine works by activating muscarinic acetylcholine receptors on the ciliary muscle and iris sphincter in the eye. This parasympathomimetic action causes contraction of the ciliary muscle (accommodation) and pupil constriction, which can improve near vision and potentially reduce intraocular pressure. The ophthalmic solution formulation allows direct local delivery to ocular tissues.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aceclidine ophthalmic solution

What is Aceclidine ophthalmic solution?

Aceclidine ophthalmic solution is a Muscarinic receptor agonist drug developed by LENZ Therapeutics, Inc, indicated for Presbyopia (age-related loss of accommodation), Potentially glaucoma or ocular hypertension.

How does Aceclidine ophthalmic solution work?

Aceclidine is a cholinergic agonist that stimulates muscarinic receptors in the eye to increase accommodation and improve near vision.

What is Aceclidine ophthalmic solution used for?

Aceclidine ophthalmic solution is indicated for Presbyopia (age-related loss of accommodation), Potentially glaucoma or ocular hypertension.

Who makes Aceclidine ophthalmic solution?

Aceclidine ophthalmic solution is developed by LENZ Therapeutics, Inc (see full LENZ Therapeutics, Inc pipeline at /company/lenz-therapeutics-inc).

Is Aceclidine ophthalmic solution also known as anything else?

Aceclidine ophthalmic solution is also known as LNZ100, Aceclidine.

What drug class is Aceclidine ophthalmic solution in?

Aceclidine ophthalmic solution belongs to the Muscarinic receptor agonist class. See all Muscarinic receptor agonist drugs at /class/muscarinic-receptor-agonist.

What development phase is Aceclidine ophthalmic solution in?

Aceclidine ophthalmic solution is in Phase 3.

What are the side effects of Aceclidine ophthalmic solution?

Common side effects of Aceclidine ophthalmic solution include Ocular discomfort or irritation, Blurred vision, Headache, Brow ache.

What does Aceclidine ophthalmic solution target?

Aceclidine ophthalmic solution targets Muscarinic acetylcholine receptors (M1, M3) and is a Muscarinic receptor agonist.

Related